This is an open label study on the pharmacokinetics and safety of ciclosporin in patients with severe traumatic brain injury, who require intensive care unit admission and monitoring of intracranial pressure via a ventricular catheter. 20 patients will be screened, and subsequently enrolled after clinical stabilisation. Thereafter, patients will receive 2.5 mg/kg bolus dose infusion of ciclosporin, followed by either 5 mg/kg/day or 10 mg/kg/day of ciclosporin as continuous infusion for 5 days+3 days monitoring at the intensive care unit. After an additional 30 days, a follow-up phone call will be made to the patient, or the patient's nursing staff, checking patient status and serious adverse events. The two dose levels will be investigated in 10 patients each, starting with the lower dose level for the first 10 patients. Patients will have samples of blood and cerebrospinal fluid drawn at pre-defined time points during the study for pharmacokinetic assessment and evaluation of biomarkers. Bedside monitoring with microdialysis and brain tissue oxygenation will be performed. The safety monitoring includes nephrotoxicity, hepatotoxicity, monitoring of intracranial pressure (ICP), infections monitoring and adverse events collection and reporting.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
Dept. of Neurosurgery, Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Non-compartmental analysis of pharmacokinetics (PK) of Ciclosporin in whole blood
Peak Plasma Concentration (Cmax) of Ciclosporin and Area under the blood concentration versus time curve (AUC) of Ciclosporin. This will characterise the pharmacokinetic profile of the two chosen dosing regimens of ciclosporin in severe Traumatic Brain Injury (TBI) patients.
Time frame: Prespecified timepoints during 8 days (PK)
Incidence of adverse events
Including: 1. Ciclosporin levels in whole blood. 2. Markers of nephrotoxicity: plasma creatinine plasma Cystatin-C and blood urea nitrogen. 3. Markers of hepatotoxicity: prothrombin time (PT), aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin. 4. Intracranial Pressure (ICP) 5. Assessment of infections: according to standard procedures at intensive care unit.
Time frame: 38 days
Ciclosporin levels in cerebrospinal fluid (CSF)
The CSF samples will be drawn from the EVD-catheter at the same time points as in blood to document central nervous system penetration of ciclosporin
Time frame: Prespecified timepoints during 8 days
Safety biomarkers for nephrotoxicity
Kidney Injury Molecule (KIM)-1, creatinine and Cystatin-C in urine samples
Time frame: Measured at prespecified timepoints during 8 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.